Home / Companies / Lexicon Pharmaceuticals, Inc. / 30 Apr 2026
Lexicon Pharmaceuticals, Inc.: meeting of 30 Apr 2026
Votes reported on Form N-PX, item by item
109 Form N-PX filers reported votes at the Lexicon Pharmaceuticals, Inc. meeting of 30 Apr 2026. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 82.1% of reported votes for; 4 filers withheld from or voted against at least one nominee.
114 vote records from 19 filers. 1 of the 18 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
141 vote records from 109 filers. 1 of the 98 filers that marked the item either way voted against management. 11 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
38 vote records from 19 filers. 1 of the 18 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
37 vote records from 18 filers. 0 of the 17 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
82 vote records from 20 filers. 0 of the 19 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | No report | For | No report |
| Fidelity | For | For | For |
| Dimensional | No report | For | No report |
| State Street and SPDR | No report | For | No report |
| Invesco | For | For | For |
| Charles Schwab | For | For | For |
| John Hancock and Manulife | For | For | For |
| Morgan Stanley, Eaton Vance and Calvert | No report | For | No report |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | No report | For | No report |
| Northern Trust and FlexShares | Split or no vote | For | Split or no vote |
| Victory Capital | For | For | For |
| Guggenheim and Rydex | For | For | For |
| BNY Mellon | No report | For | No report |
| Neuberger Berman | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Lexicon Pharmaceuticals, Inc. meeting?
109 Form N-PX filers reported votes at the meeting of 30 Apr 2026. On say-on-pay, 1 of 98 voted against management (1.0%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Lexicon Pharmaceuticals, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Lexicon Pharmaceuticals, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Lexicon Pharmaceuticals, Inc. with a meeting date within three days of 30 Apr 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.